Abstract:The Megalencephaly-capillary malformation (MCAP) syndrome is an overgrowth syndrome caused by mosaic gain-of-function (activating) variants in the PIK3CA gene. This multi-system disorder is characterized by megalencephaly (MEG) or hemimegalencaphly (HMEG), cutaneous vascular malformations, variable somatic overgrowth, digital anomalies, and connective tissue laxity. Epilepsy is commonly associated with MCAP, and a subset of affected individuals have cortical malformations which may require resective epilepsy surgery. Similar to other mosaic disorders, establishing a molecular diagnosis for individuals with MCAP is largely achieved by sequencing affected or lesional tissues (such as brain or skin), with a very low diagnostic yield from testing peripheral samples (such as peripheral blood). Therefore, in individuals where lesional tissues are scarce or unavailable, including individuals with MCAP who are not candidates for epilepsy surgery, establishing a molecular diagnosis can be challenging. CSF-derived cell free DNA (cfDNA) has recently emerged as novel tool for genomic profiling in brain tumors, as well more recently other types of PIK3CA-related somatic disorders including lymphatic and vascular malformations. Here we report on the utility of CSF-derived cfDNA for the molecular diagnosis of an individual with MCAP syndrome harboring a highly mosaic PIK3CA variant (c.3139C>T, p.His1047Tyr). The proband is a male who was identified shortly after birth to have megalencephaly, right hemihypertrophy as well as abnormal skin pigmentation with extensive deep purple-red vascular markings widely distributed over the body. Brain magnetic resonance imaging (MRI) revealed significant megalencephaly, with asymmetric cerebral hemispheres and cerebellar tonsillar herniation. On follow-up evaluations, he developed progressive hydrocephalus requiring ventriculoperitoneal shunt placement at age six months. He also underwent laser ablation treatment for the extensive capillary malformations on his upper lip and right cheek. Medical history is also notable for intestinal lymphangiectasia leading to episodes of diarrhea and nutritional deficiency during early childhood. Developmentally, he had severe delays in gross motor development, including inability to walk independently until after three years of age, moderate speech delays and significant neurobehavioral issues. Serial physical examinations confirmed his progressive macrocephaly as well as right hemihypertrophy involving the face and extremities with several measurements performed, as follows: at age three years, right ear was 6 cm (97th percentile) while the left was 4.7 cm (50th percentile); right hand measured 9.9 cm (3rd percentile), and left hand measured 9.3 cm (∼ 1st percentile). His occipito-frontal circumference (OFC) at three years of age was 58.5 cm (+5.8 SD) and later increased to 65.5 cm (+7 SD) at 19 years of age. He also had pinpoint elevated capillary malformations that range in size from 5 x 5 mm to approximately 1 x 1 cm, with a prominent venous pattern all over the scalp. Following laser ablation, he had residual vascular staining of his right cheek, on his right upper lip, and more extensive irregular vascular pattern over his left arm. During his late childhood, he had recurrent lymphedema, protein-losing enteropathy and pleural effusions. At age 19 years, he was admitted to the pediatric intensive care unit (PICU) due to recurrent pleural effusions. He was later found to have atypical lymphocytes in pleural fluid with increased fluorodeoxyglucose (FDG) uptake in bilateral cervical, mediastinal, abdominal, and pelvic lymph nodes on entire body Positron Emission Tomography (PET) imaging. Excisional biopsy of cervical lymph nodes showed sheets of atypical cells with large, vesicular nuclei with prominent nucleoli and scanty cytoplasm. Immunocytochemical staining and flow cytometry immunotyping confirmed the diagnosis of diffuse large B-cell lymphoma (DLBCL, stage III b). He underwent a lumbar puncture (LP) for tumor staging as well as during the course of chemotherapy, and additional CSF was collected for molecular diagnostics as well. CSF-derived cfDNA was collected in Cell-Free DNA BCT tubes and processed using established protocols. He completed chemotherapy without further remission. Brain MRI obtained during this period showed asymmetric megalencephaly with mildly abnormal cortical gyral pattern, asymmetric dysplastic ventricles and cerebellar tonsillar ectopia. He only had three brief seizures for a short period of time during his chemotherapy which responded well to levetiracetam. The proband first presented to our genetic team and underwent molecular diagnostic testing around the time when his lymphoma was diagnosed. We performed targeted sequencing using the Megaplex panel at the University of Washington. This panel offers ultra-deep sequencing of 63 megalencephaly and overgrowth genes. Testing was performed on several samples including CSF-derived cfDNA, peripheral blood and cultured fibroblasts from affected skin from the left arm. GRCh37/hg19 assembly was used. A mosaic variant in PIK3CA (NM_006218.2: c.3139 C>T, p.His1047Tyr) was identified in CSF cfDNA at variant allele fractions (VAF) of 3.08% (var/ref read: 14/440), as well as in peripheral blood (VAF 2%; var/ref read: 8/394), and skin fibroblasts (VAF 37.31%; var/ref read: 673/1131). These results molecularly confirmed his diagnosis of MCAP as well as provided insights on the range of mosaicism across these samples. Cell-free DNA-based diagnostic approaches have become robust and reliable molecular tools in prenatal genetics, as well as for cancer diagnosis, treatment, and monitoring. Plasma and cystic fluid cfDNA have also been recently successfully used to detect somatic variants associated with PIK3CA- associated lymphatic and vascular malformations. Altogether, these lines of evidence suggest that cfDNA from various body fluids in direct contact with pathological tissues can be utilized as a “proxy” for molecular diagnostics. In this study, we report on the molecular diagnostic yield of cfDNA from CSF in an individual with MCAP syndrome who had significant neurological involvement. Using CSF-derived cfDNA has several important clinical implications in mosaic brain disorders. cfDNA from CSF provides a more practical and less invasive option to establish a molecular diagnosis in individuals with these disorders. These approaches are particularly useful for individuals with isolated or very tissue-restricted mosaicism in the brain, or for individuals who are not candidates for epilepsy surgery. Further, establishing a molecular diagnosis by the identification of a PI3K-AKT-MTOR pathogenic variant prior to undergoing epilepsy surgery could shift the existing paradigm for testing and treatment strategies, especially as repurposed PI3K-AKT-MTOR pathway-inhibitors are becoming more widely available, and may become earlier lines of therapy for epilepsy in affected individuals.

Identification of a mosaic MTOR variant in purified neuronal DNA in a patient with focal cortical dysplasia using a novel depth electrode harvesting technique

Somatic Variants in New Candidate Genes Identified in Focal Cortical Dysplasia Type II

Analysis of DNA from brain tissue on stereo-EEG electrodes reveals mosaic epilepsy-related variants

Detecting somatic variants in purified brain DNA obtained from surgically implanted depth electrodes in epilepsy

Detection of brain somatic variation in epilepsy-associated developmental lesions

Cell-type-informed genotyping of mosaic focal epilepsies reveals cell-autonomous and non-cell-autonomous disease-associated transcriptional programs

Somatic variants as a cause of drug‐resistant epilepsy including mesial temporal lobe epilepsy with hippocampal sclerosis

The clinico-pathological characterisation of focal cortical dysplasia type IIb genetically defined by MTOR mosaicism

Identification of Genetic Characteristics in Pediatric Epilepsy with Focal Cortical Dysplasia Type 2 Using Deep Whole-Exome Sequencing

The clinico-pathological characterisation of focal cortical dysplasia type IIb genetically defined by <i>MTOR</i> mosaicism

High-Resolution Multimodal Profiling of Human Epileptic Brain Activity via Explanted Depth Electrodes

Spatial omics reveals molecular changes in focal cortical dysplasia type II

Somatic variant analysis of resected brain tissue in epilepsy surgery patients

Transcriptomic profiling of high- and low-spiking regions reveals novel epileptogenic mechanisms in focal cortical dysplasia type II patients

Automated Detection of Focal Cortical Dysplasia Type II with Surface-Based Magnetic Resonance Imaging Postprocessing and Machine Learning

Detection of Brain Somatic Mutations in Cerebrospinal Fluid from Refractory Epilepsy Patients

Interpretable Surface-Based Detection of Focal Cortical Dysplasias: a Multi-centre Epilepsy Lesion Detection Study

Leveraging multiple approaches for the detection of pathogenic deep intronic variants in developmental and epileptic encephalopathies: A case report

Anti-seizure gene therapy for focal cortical dysplasia

Ep097: the Utility of CSF-derived Cell Free DNA in Molecular Diagnostics for the Megalencephaly-capillary Malformation (MCAP) Syndrome: A Case Report

Rational Search for Genes in Familial Cortical Myoclonic Tremor with Epilepsy, Clues from Recent Advances.